Epidermal Growth Factor Receptor Family and Its Role in Gastric Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Dec 19

PMID 31850207

Citations 57

Authors

Chiara Arienti

Sara Pignatta

Anna Tesei

Affiliations

Soon will be listed here.

Abstract

Despite the gradual decrease in incidence, gastric cancer is still the third leading cause of cancer death worldwide. Although chemotherapy enhances overall survival and quality of life in advanced disease, the median overall survival is < 12 months. In recent years, the human epidermal growth factor receptor (ErbB) family has been extensively investigated in gastric cancer. The ErbB family is composed of four closely-related members: ErbB-1 (HER1 or epidermal growth factor receptor, EGFR), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4), all of which play a critical role in regulating cell growth, proliferation and migration of tumors. It is well known that gastric cancer overexpresses HER in a heterogeneous pattern, especially EGFR, and HER2. HER3 is another important member of the ErbB family that preferentially activates the phosphatidylinositol 3-kinase (PI3K) pathway. Furthermore, its heterodimerization with HER2 seems fundamental for steering HER2-overexpressing breast cancer tumor growth. Less is known about the impact of HER4 on gastric cancer. Improved survival from the use of trastuzumab has paved the way for ErbB receptor family-targeted treatments in gastric cancer. However, unlike trastuzumab, ErbB receptor-targeted drugs have not consistently maintained the encouraging results obtained in preclinical and early clinical trials. This may be attributable to the intrinsic heterogeneity of gastric cancer and/or to the lack of standardized test quality for established biomarkers used to evaluate these biological targets. This review presents an overview of the most recent clinical studies on agents targeting the ErbB family in gastric cancer.

Citing Articles

PLASMA: Partial LeAst Squares for Multiomics Analysis.

Yamaguchi K, Abdelbaky S, Yu L, Oakes C, Abruzzo L, Coombes K Cancers (Basel). 2025; 17(2).

PMID: 39858069 PMC: 11763701. DOI: 10.3390/cancers17020287.

Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer.

Li S, Sun M, Cui Y, Guo D, Yang F, Sun Q EMBO J. 2025; 44(5):1464-1487.

PMID: 39838173 PMC: 11876641. DOI: 10.1038/s44318-025-00363-x.

Kindlin-1 promotes gastric cancer cell motility through the Wnt/β-catenin signaling pathway.

Jang J, Jung J, Kang H, Kim W, Kim W, Lee H Sci Rep. 2025; 15(1):2481.

PMID: 39833319 PMC: 11756408. DOI: 10.1038/s41598-025-86220-7.

Selecting Targets for Molecular Imaging of Gastric Cancer: An Immunohistochemical Evaluation.

Houvast R, van Duijvenvoorde M, Thijse K, de Steur W, de Geus-Oei L, Crobach A Mol Diagn Ther. 2024; 29(2):213-227.

PMID: 39541080 PMC: 11860997. DOI: 10.1007/s40291-024-00755-5.

EGFR-directed antibodies promote HER2 ADC internalization and efficacy.

Gupta A, Michelini F, Shao H, Yeh C, Drago J, Liu D Cell Rep Med. 2024; 5(11):101792.

PMID: 39437778 PMC: 11604483. DOI: 10.1016/j.xcrm.2024.101792.

References

Aydin K, Okutur S, Bozkurt M, Turkmen I, Namal E, Pilanci K . Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study. Oncol Lett. 2013; 7(1):255-259. PMC: 3861593. DOI: 10.3892/ol.2013.1662. View

Lockhart A, Reed C, Decker P, Meyers B, Ferguson M, Oeltjen A . Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Ann Oncol. 2014; 25(5):1039-44. PMC: 5808674. DOI: 10.1093/annonc/mdu091. View

Fedi P, PIERCE J, Di Fiore P, Kraus M . Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol. 1994; 14(1):492-500. PMC: 358399. DOI: 10.1128/mcb.14.1.492-500.1994. View

Zhu Y, Sullivan L, Nair S, Williams C, Pandey A, Marrero L . Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res. 2006; 66(16):7991-8. DOI: 10.1158/0008-5472.CAN-05-4397. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J . EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol. 2008; 15(4):1193-201. DOI: 10.1245/s10434-007-9771-3. View

Shimoyama S . Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). Mol Clin Oncol. 2014; 2(2):175-181. PMC: 3917765. DOI: 10.3892/mco.2013.218. View

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

10.

Kainulainen V, Sundvall M, Maatta J, Santiestevan E, Klagsbrun M, Elenius K . A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem. 2000; 275(12):8641-9. DOI: 10.1074/jbc.275.12.8641. View

11.

Seshacharyulu P, Ponnusamy M, Haridas D, Jain M, Ganti A, Batra S . Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):15-31. PMC: 3291787. DOI: 10.1517/14728222.2011.648617. View

12.

Ni C, Murphy M, Golde T, Carpenter G . gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001; 294(5549):2179-81. DOI: 10.1126/science.1065412. View

13.

Le Chevalier T, Smith F, Harter W, Schein P . Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma. Semin Oncol. 1985; 12(1):46-53. View

14.

Wang Y, Bennett C, Pan T . Endoscopic mucosal resection for early gastric cancer. Cochrane Database Syst Rev. 2006; (1):CD004276. DOI: 10.1002/14651858.CD004276.pub2. View

15.

Janjigian Y, Werner D, Pauligk C, Steinmetz K, Kelsen D, Jager E . Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012; 23(10):2656-2662. DOI: 10.1093/annonc/mds104. View

16.

Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden P, Haglund U . Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8(2):163-8. DOI: 10.1023/a:1008243606668. View

17.

Kim M, Lee H, Lee H, Jeon Y, Yang H, Kim W . EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008; 52(6):738-46. DOI: 10.1111/j.1365-2559.2008.03021.x. View

18.

Chen C, Yang J, Hu T, Xu T, Yan G, Hu S . Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res. 2013; 44(5):380-9. DOI: 10.1016/j.arcmed.2013.07.001. View

19.

Jacome A, Wohnrath D, Scapulatempo Neto C, Carneseca E, Serrano S, Viana L . Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. Gastric Cancer. 2013; 17(1):76-86. PMC: 3889290. DOI: 10.1007/s10120-013-0236-z. View

20.

Songun I, Putter H, Meershoek-Klein Kranenbarg E, Sasako M, van de Velde C . Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010; 11(5):439-49. DOI: 10.1016/S1470-2045(10)70070-X. View